CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations

Journal of Clinical Pharmacology

Volumn 40, Issue 1, 2000, Pages 58-66

  Alfaro, Cam L ^a,b,d   Lam, Y W Francis ^a,b   Simpson, Joseph ^c   Ereshefsky, Larry ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Alamo Mental Health Group   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; FLUOXETINE; PAROXETINE; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG TOLERANCE; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; FLUOXETINE; HUMANS; ISOENZYMES; PAROXETINE; PHENOTYPE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0033710657     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008702     Document Type: Article

References (35)

1. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants
2. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors
3. Fluoxetine: A serotonin-specific second-generation antidepressant
4. Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal
5. Drug-drug interactions involving antidepressants: Focus on venlafaxine
6. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system
7. Drug interactions with newer antidepressants: Role of human cytochromes P450
8. Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs
9. Influence of fluoxetine on plasma levels of desipramine
10. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction
11. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies, and phenotypic consequences
12. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
13. The genetic polymorphism of debrisoquine/sparteine metabolism: Clinical aspects
14. Venlafaxine oxidation in vitro is catalysed by CYP2D6
15. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
16. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo
17. The oxidative metabolism of metoprolol in human liver microsomes: Inhibition by the selective serotonin reuptake inhibitors
18. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline
19. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine
20. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection
21. Intraindividual variability of the dextromethorphan/dextrorphan ratio in extensive metabolizers
22. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping
23. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine
24. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers
25. Effect of venlafaxine versus fluoxetine on the metabolism of dextromethorphan, a CYP2D6 marker
26. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism
27. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
28. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
29. Human cytochromes mediating N-demethylation of fluoxetine in vitro
30. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression
31. Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study
32. Clinical implications of dose-dependent cytochrome P-450 drug-drug interactions with antidepressants
33. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline
34. In vivo relationship of SSRI plasma concentration with CYP2D6 inhibition
35. CYP2D6 inhibition in patients treated with sertraline